Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study

Overview of attention for article published in Advances in Therapy, October 2019

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 22 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 2,094 followers.

RT @AdvancesTherapy: Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, #HCV-Infected Patients with APRI ≤ 1 in…

06 Nov 2019

Reply Repost Favourite

Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, #HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study. Read the full text and accompanying plain language summary here: https://t.co/lWvbVQYOxA #He

23 Oct 2019

Reply Repost Favourite